News & Updates
AMP PD Public Target Explorer has Launched
The AMP PD Target Explorer is a public resource with open access for exploring nominated genes and proteins from AMP PD data that might be implicated in Parkinson's Disease. The Target Explorer integrates many AMP PD work streams focused on identifying new biomarkers and novel drug targets, with the goal of accelerating treatment discovery for patients with Parkinson's Disease.
With the Target Explorer, researchers can explore targets from genomics, transcriptomics, and proteomics data, contributed by the AMP PD community. Use the Target Explorer to compare your findings with the findings of other researchers by entering your list of potential targets into the search engine to find out where they appear in other researchers’ analyses.
All Target Lists in the Target Explorer have corresponding methods definitions, dictionaries, and links to publications where applicable. Many of these lists will have downloadable analysis data and corresponding notebooks in Terra. With these notebooks, you can see how AMP PD researchers generated their target lists, learn how to execute these analyses in the cloud, or replicate them and try your own modifications to suit your investigation.
How can I contribute my PD targets and biomarkers?
Nominating targets benefits your study and the AMP PD program. When you contribute your target nominations, it will be added to the AMP PD Target and Biomarker list with existing nominations to facilitate search and discovery This also provides your research greater exposure with links back to your data and your publications as the definitive source for Target Explorer users to read, reuse, and reference in their work.
The Accelerating Medicines Partnership® (AMP®) program is a public-private partnership between the National Institutes of Health (NIH), multiple biopharmaceutical and life sciences companies, and non-profit organizations. Learn more about AMP PD here.
Managed through the Foundation for the NIH (FNIH), AMP unites resources of NIH and private partners to improve our understanding of disease pathways and transform current models for developing new treatments by:
- Identifying new targets, biomarkers and development paradigms
- Developing leading-edge tools and technologies
- Collecting large scale datasets and supporting analytics for open analysis by the research community
- Generation of consensus platforms and procedures